Safety update for #filgotinib in #RA over ~2.2yrs treatment 👉🏼Well-tolerated with no ne safety concerns since 2020 👉🏼AE incidence rates decreased or remained stable 👉🏼Slight incr rates of NMSC & non-NMSC malignancies Abs#1698 #ACR21 @RheumNow https://t.co/0jbZFVgiyN https://t.co/yOlntLwQlU